Tom Fardon

1.1k total citations
25 papers, 703 citations indexed

About

Tom Fardon is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology and Allergy. According to data from OpenAlex, Tom Fardon has authored 25 papers receiving a total of 703 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 18 papers in Physiology and 5 papers in Immunology and Allergy. Recurrent topics in Tom Fardon's work include Asthma and respiratory diseases (17 papers), Respiratory and Cough-Related Research (14 papers) and Inhalation and Respiratory Drug Delivery (7 papers). Tom Fardon is often cited by papers focused on Asthma and respiratory diseases (17 papers), Respiratory and Cough-Related Research (14 papers) and Inhalation and Respiratory Drug Delivery (7 papers). Tom Fardon collaborates with scholars based in United Kingdom, United States and Italy. Tom Fardon's co-authors include Brian J. Lipworth, Martyn Barnes, Lesley C. McFarlane, Daniel K.C. Lee, Kay Haggart, Peter A. Williamson, Stuart Schembri, Arun Nair, Daniel Menzies and Mudher Al-Khairalla and has published in prestigious journals such as JAMA, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Tom Fardon

25 papers receiving 670 citations

Peers

Countries citing papers authored by Tom Fardon

Since Specialization

Citations

This map shows the geographic impact of Tom Fardon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Fardon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Fardon more than expected).

Fields of papers citing papers by Tom Fardon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Fardon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Fardon. The network helps show where Tom Fardon may publish in the future.

Co-authorship network of co-authors of Tom Fardon

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Fardon. A scholar is included among the top collaborators of Tom Fardon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Fardon. Tom Fardon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world effects of tezepelumab on small airway dysfunction in severe refractory asthma 2025 ·Annals of Allergy Asthma & Immunology ·Robert Greig, Rory Chan, Tom Fardon, Brian J. Lipworth	9
2	Real-life evaluation of novel forced expiratory ratios with asthma exacerbations and symptoms 2025 ·Annals of Allergy Asthma & Immunology ·(unknown), (unknown), Dania Ahmed, Remo Poto, Atanu Bhattacharjee, Robert Greig, (unknown), Frans H. de Jongh, (unknown), Tom Fardon, Brian J. Lipworth, Rory Chan	1
3	Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis 2020 ·Thorax ·(unknown), (unknown), Jackie Donovan, Simon Finch, Gan Liang Tan, Tom Fardon, Robert Wilson, (unknown), Michael R. Loebinger, James D. Chalmers	17
4	The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis 2018 ·European Respiratory Journal ·Pieter Goeminne, B. Cox, Simon Finch, Michael R. Loebinger, Pallavi Bedi, Adam T. Hill, Tom Fardon, Kees de Hoogh, Tim S. Nawrot, James D. Chalmers	37
5	Comparative analysis of the predictive utility of clinical disease severity scores for non-cystic fibrosis bronchiectasis 2014 ·European Respiratory Journal ·Melissa J. McDonnell, Pieter Goeminne, (unknown), John M. Davison, Sara Lonni, Lucy Poppelwell, Waleed Salih, Alberto Pesci, Tom Fardon, Lieven Dupont, Adam T. Hill, Anthony De Soyza, James D. Chalmers	1
6	An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis 2014 ·Journal of Cystic Fibrosis ·Graham Devereux, (unknown), (unknown), Shona Fielding, Robert C. J. Muirhead, Jeff Brady, Christal Grierson, Richard Brooker, J H Winter, Tom Fardon, Jonathan McCormick, Jeffrey Huang, Douglas K. Miller	42
7	A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections 2013 ·Journal of Antimicrobial Chemotherapy ·Colin Murray, (unknown), Margaret Lloyd, (unknown), Tom Fardon, Stuart Schembri, James D. Chalmers	27
8	Proof of concept study to evaluate step‐down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma 2010 ·British Journal of Clinical Pharmacology ·(unknown), Peter A. Williamson, Philip Short, Tom Fardon, Brian J. Lipworth	6
9	Supervised step-down of inhaled corticosteroids in the community – An observational study 2010 ·Respiratory Medicine ·(unknown), Catherine Jackson, Tom Fardon, Peter A. Williamson, Sriram Vaidyanathan, (unknown), Brian J. Lipworth	18
10	An in vivo and in vitro comparison of inhaled steroid delivery via a novel vortex actuator and a conventional valved holding chamber 2007 ·Annals of Allergy Asthma & Immunology ·Daniel Menzies, Arun Nair, Tom Fardon, Martyn Barnes, Patricia Burns, Brian J. Lipworth	4
11	Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate 2007 ·British Journal of Clinical Pharmacology ·(unknown), Tom Fardon, Daniel K.C. Lee, Kay Haggart, Lesley C. McFarlane, Brian J. Lipworth, Günther Hochhaus	13
12	The Functional Consequence of the Glu298Asp Polymorphism of the Endothelial Nitric Oxide Synthase Gene in Young Healthy Volunteers 2007 ·Cardiovascular Drug Reviews ·(unknown), (unknown), Andrew Cassidy, Robert J. Butler, Anna Maria Choy, Tom Fardon, Allan D. Struthers, Chim C. Lang	36
13	Effects of intranasal corticosteroid on nasal adenosine monophosphate challenge in persistent allergic rhinitis* 2006 ·Allergy ·Martyn Barnes, (unknown), (unknown), Robert D. Gray, Tom Fardon, Brian J. Lipworth	10
14	A comparison of 2 extrafine hydrofluoroalkane-134a–beclomethasone formulations on methacholine hyperresponsiveness 2006 ·Annals of Allergy Asthma & Immunology ·Tom Fardon, Patricia Burns, Martyn Barnes, Brian J. Lipworth	24
15	Effects of levocetirizine as add‐on therapy to fluticasone in seasonal allergic rhinitis 2006 ·Clinical & Experimental Allergy ·Martyn Barnes, (unknown), Tom Fardon, Brian J. Lipworth	55
16	A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma 2006 ·Respiratory Medicine ·Tom Fardon, Kay Haggart, Daniel K.C. Lee, Brian J. Lipworth	68
17	Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma 2005 ·Annals of Allergy Asthma & Immunology ·Tom Fardon, Daniel K.C. Lee, (unknown), Brian J. Lipworth	10
18	Evaluation of an Abbreviated Adenosine Monophosphate Bronchial Challenge 2005 ·CHEST Journal ·Tom Fardon, (unknown), Brian J. Lipworth	3
19	Adrenal Suppression with Dry Powder Formulations of Fluticasone Propionate and Mometasone Furoate 2004 ·American Journal of Respiratory and Critical Care Medicine ·Tom Fardon, Daniel K.C. Lee, Kay Haggart, Lesley C. McFarlane, Brian J. Lipworth	63
20	Comparative cutoff points for adenosine monophosphate and methacholine challenge testing 2004 ·Annals of Allergy Asthma & Immunology ·Tom Fardon, (unknown), (unknown), Brian J. Lipworth	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact